Clinical trials: STD
HIV Infections
Safety and Effectiveness of the Oral HIV Entry Inhibitor Vicriviroc in HIV Infected Patients
New treatment options are critical for treatment-experienced HIV infected patients with drug resistance. HIV entry inhibitors have been shown effective in patients with resistance to other anti-HIV drugs.
- Trial name
- NCT00082498
- Testing
- SCH-D (vicriviroc)
- Where
- 30 sites in United States
- Volunteers
- 119 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
"OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
Lopinavir/ritonavir monotherapy may maintain virologic suppression in patients who have been undetectable for six months while on triple drug antiretroviral therapy.
- Trial name
- NCT00114933
- Testing
- Stopping nucleosides and continuing lopinavir/ritonavir monotherapy
- Where
- 28 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Arribas, Jose R., M.D.
HIV, Drug Addiction
Treating South African Pregnant Women for Methamphetamine
The purpose of this study was to develop and initially evaluate an efficacious, comprehensive, culturally sensitive, women-centered model of care for pregnant South African women by adapting and refining PI Jones'…
- Trial name
- NCT01386138
- Testing
- Psycho-education, Experimental
- Where
- South Africa
- Volunteers
- 60 people
- Sponsor
- RTI International
HIV Infection
Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure
HIV-1 infected subjects with CD4 nadir > 200 cells/mm3, no history of virologic failure and plasma HIV RNA <50 copies/mL for at least 48 weeks while on any United States Department of Health and Human Services (DHHS) recommended…
- Trial name
- ASPIRE (NCT02263326)
- Testing
- dolutegravir, lamivudine, Continue current antiretroviral regimen
- Where
- 7 sites in United States
- Volunteers
- 89 people
- Sponsor
- Babafemi Taiwo
HIV/AIDS
Adolescent Master Protocol for Participants 18 Years of Age or Older - Lite
This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection as they transition to adulthood.
- Trial name
- AMP Up Lite (NCT03279185)
- Where
- 9 sites in United States
- Volunteers
- 334 people
- Sponsor
- Harvard School of Public Health (HSPH)
Viral Associated Malignancies, Kaposi Sarcoma
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
Background: Less toxic and more effective treatments are needed for cancers caused by viruses. These cancers include Hodgkin and non-Hodgkin lymphoma, hepatocellular carcinoma, head and neck cancer, nasopharyngeal carcinoma…
- Conditions
- Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated Lymphomas
- Trial name
- NCT04902443
- Testing
- Pomalidomide, Nivolumab
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
HIV-1, HIV Infections
A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
This three stage study will evaluate the safety and tolerability of MRKAd5 HIV-1 Gag Vaccine. In Stage I subjects will be randomized to receive the vaccine at 1x10^9 viral particles/dose (vp/d) or placebo.
- Trial name
- NCT00849732
- Testing
- V520, Comparator: V520 (1x10^9 vp/d), Comparator: V520 (1x10^10 vp/d)
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HIV Disease Progression
Progression of HIV-Disease Under Low Dose Corticosteroids
There has been reports that low dose prednisolone stabilizes CD4-counts in HIV infected individuals. However, until now, there are no prospective randomized studies on the use of corticosteroids in latent HIV disease.
- Trial name
- ProCort1 (NCT01299948)
- Testing
- Prednisolone
- Where
- Tanzania
- Volunteers
- 326 people
- Sponsor
- Medical Mission Institute, Germany
HIV Infections, Acquired Immune Deficiency Syndrome
Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients
The purpose of this study is to determine any adverse effects of PRO 542 after administration and to determine the anti-HIV effects of PRO 542 in the patient.
- Trial name
- NCT00055185
- Testing
- CD4-IgG2 (PRO 542)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
HIV Infections
Comparative Pharmacokinetics (PK) Study of Efavirenz or Lopinavir/Ritonavir Between Older and Younger HIV-Infected Adults
HIV infected patients, aged </= 35 years and aged >/= 55 years, who are regularly taking either efavirenz (EFV) or lopinavir/ritonavir (Lop/r) as part of their antiretroviral regimen are being asked to spend 12 hours at the…
- Trial name
- NCT00179335
- Testing
- Blood drawing to determine drug levels
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Albert Einstein College of Medicine
Human Immunodeficiency Virus, Perinatal Depression
Adaptation of the Friendship Bench Intervention for HIV-infected Perinatal Women in Lilongwe
In many sub-Saharan African countries, the scale-up of lifelong antiretroviral treatment (ART) to all pregnant and breastfeeding women under Option B+ has the potential to radically improve maternal health and reduce…
- Trial name
- Periscope (NCT04143009)
- Testing
- Enhanced Friendship Bench, Enhanced Standard Care (Control), Adapted Friendship Bench
- Where
- 3 sites in Malawi
- Volunteers
- 92 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir
Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or…
- Trial name
- NCT00120393
- Testing
- atazanavir/ritonavir +2 NRTIs (immediate Switch Group), LPV/r +2 NRTIs (Delayed/optional Switch Group)
- Where
- 14 sites in United States, Canada
- Volunteers
- 192 people
- Sponsor
- Bristol-Myers Squibb
Pregnancy, Sexually Transmitted Infections
Evaluation of the Effectiveness of the POWER Through Choices Program
The purpose of this study is to evaluate the effectiveness of the POWER Through Choices (PTC) curriculum in increasing contraceptive use and delaying sexual initiation among youth living in group foster care homes.
- Trial name
- NCT01565304
- Testing
- POWER Through Choices
- Where
- 3 sites in United States
- Volunteers
- 1,039 people
- Sponsor
- Mathematica Policy Research, Inc.
HIV
HIV Clinic-Based Intervention to Improve ART Adherence and Prevent HIV Transmission
This research, co-sponsored by the Centers for Disease Control and Prevention and the National Institute of Mental health, is conducted at six HIV clinics in the U.S.
- Trial name
- APTcare (NCT02044484)
- Testing
- Multi-component intervention
- Where
- 6 sites in United States
- Volunteers
- 2,794 people
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections, Hepatitis C
Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus
The purpose of this study is to find if the Single Photon Emission Computed Tomography (SPECT) scan is as effective as a liver biopsy (using a special needle to remove tissue from the liver) in examining liver damage in patients…
- Trial name
- NCT00006643
- Where
- 11 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women
The purpose of this study is to determine the safety, tolerance, and metabolism of single-dose and multiple-dose abacavir (ABC) in HIV-exposed infants receiving standard postnatal treatment with zidovudine (ZDV).
- Trial name
- NCT00000864
- Testing
- Abacavir sulfate, Zidovudine
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Cytopenias
A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia
To evaluate the safety of repeated courses of sargramostim ( recombinant granulocyte-macrophage colony-stimulating factor; GM-CSF ) administered subcutaneously to patients with HIV infection and leukopenia.
- Trial name
- NCT00002007
- Testing
- Zidovudine, Sargramostim
- Where
- United States
- Sponsor
- Sandoz
Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis Infection
Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection
The frequency of Chlamydia trachomatis and Neisseria gonorrhoeae coinfection can vary depending on their individual incidence and prevalence rates.Single-agent therapy with ceftriaxone is the preferred regimen for treatment of…
- Trial name
- NCT05216744
- Testing
- Ceftriaxone 1000mg + doxycycline 100 mg, Cefixime 800mg + doxycycline 100 mg
- Where
- Vietnam
- Volunteers
- 125 people
- Sponsor
- Haiphong University of Medicine and Pharmacy
HIV
Clinical and Immunologic Monitoring of Patients With Known or Suspected HIV Infection
This study will investigate HIV infection and associated conditions by monitoring infected patients. The study will also serve as a means for recruiting HIV-infected individuals to NIAIDs ongoing clinical and laboratory studies…
- Trial name
- NCT00789009
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection, Adverse Drug Reaction
Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study
Switching from the ritonavir-boosted protease inhibitor component to raltegravir in stable HIV-infected adult patients receiving combination therapy will demonstrate improved clinical tolerability or lipid profiles with sustained…
- Conditions
- HIV Infection, Adverse Drug Reaction, Quality of Life
- Trial name
- TaISENWITCH (NCT01679964)
- Testing
- Raltegravir switch
- Where
- 7 sites in Taiwan
- Volunteers
- 107 people
- Sponsor
- Lin, Hsi-Hsun, M.D.